Month: June 2020
FINTEPLA® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trialsCommercial launch planned for July 2020Zogenix to host an investor call tomorrow, June 26, at 8:30 AM ET / 5:30 AM PTEMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA® (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA will be launched through a restricted distribution program, called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS)...
Fusion Acquisition Corp. Announces Pricing of $305 Million Initial Public Offering
Written by Customer Service on . Posted in Public Companies.
NEW YORK, June 25, 2020 (GLOBE NEWSWIRE) — Fusion Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 30,500,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (“NYSE”) and trade under the ticker symbol “FUSE.U” beginning on June 26, 2020. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the NYSE under the symbols “FUSE” and “FUSE WS,” respectively.Fusion Acquisition Corp. is a blank-check company formed...
Akouos Announces Pricing of Initial Public Offering
Written by Customer Service on . Posted in Public Companies.
BOSTON, June 25, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, today announced the pricing of its initial public offering of 12,500,000 shares of common stock at a public offering price of $17.00 per share, for gross proceeds of $212.5 million, before underwriting discounts and commissions and offering expenses payable by Akouos. The offering is expected to close on or about June 30, 2020, subject to the satisfaction of customary closing conditions. In addition, Akouos has granted the underwriters an option for a period of 30 days to purchase up to 1,875,000 additional shares of common stock at...
Banner Corporation Announces Pricing of Subordinated Notes Offering
Written by Customer Service on . Posted in Public Companies.
WALLA WALLA, Wash., June 25, 2020 (GLOBE NEWSWIRE) — Banner Corporation (NASDAQ GSM: BANR) (“Banner”), the parent company of Banner Bank and Islanders Bank (the “Banks”), today announced the pricing of its public offering of $100.0 million aggregate principal amount of 5.00% Fixed-to-Floating Rate Subordinated Notes due 2030 (the “Notes”). The price to the public is 100% of the principal amount of the Notes. Interest on the Notes initially will accrue at a rate equal to 5.00% per annum from and including June 30, 2020 to, but excluding, June 30, 2025 or the earlier redemption date, payable semi-annually in arrears. From and including June 30, 2025 to, but excluding, June 30, 2030 or the earlier redemption date, interest will accrue at a floating rate per annum equal to a benchmark rate, which is expected to be Three-Month...
Inscape Announces Fourth Quarter and Full Year 2020 Financial Results
Written by Customer Service on . Posted in Public Companies.
HOLLAND LANDING, Ontario, June 25, 2020 (GLOBE NEWSWIRE) — Inscape (TSX: INQ), a leading designer and manufacturer of furnishings for the workplace, today announced its results of operations for the fourth quarter and full year ended April 30, 2020. “Fiscal Year 2020 results were disappointing and, similar to our entire industry, our fourth quarter in particular was significantly impacted by the COVID-19 pandemic. While safeguarding the well-being of employees is the Company’s primary concern, we have taken the necessary steps to respond to these circumstances through aggressive actions to build cash, manage expenses and invest in rapid payback opportunities in order to position the business for growth and profitability as the general economy recovers from these effects,” said Eric Ehgoetz, CEO. “Specifically, several measures...
VivoPower International PLC Announces Issuance of Stock Units
Written by Customer Service on . Posted in Public Companies.
LONDON, June 25, 2020 (GLOBE NEWSWIRE) — VivoPower International PLC (NASDAQ: VVPR, the “Company”) announces that the independent non executive board members who form the Remuneration and Nomination Committee of the Company have approved grants of restricted stock units (“RSUs”) in lieu of cash fees for the current financial period for certain of its directors, including Executive Chairman and CEO, Kevin Chin. These grants are made in accordance with the Company’s 2017 Omnibus Incentive Plan that was approved by shareholders. Details of the RSU grants are summarised below.Details of the Award of RSUs to DirectorsEach RSU entitles the holder to subscribe for an Ordinary Share at a subscription price of one penny per Ordinary Share. The RSUs have a vesting period of one year and no performance conditions. The RSUs granted will vest...
MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
Written by Customer Service on . Posted in Public Companies.
LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive preclinical findings published in Frontiers in Immunology regarding the prospect of MN-166 (ibudilast) as an adjunct treatment for glioblastoma.The publication, entitled “Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression”, was a collaborative effort between MediciNova and the Cleveland Clinic, led by Tyler Alban (doctoral candidate) and Dr. Justin Lathia, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research...
Erdene Announces Results of Annual and Special Meeting of Shareholders
Written by Customer Service on . Posted in Public Companies.
HALIFAX, Nova Scotia, June 25, 2020 (GLOBE NEWSWIRE) — Erdene Resource Development Corporation (TSX:ERD | MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce its shareholders voted in favour of all items of business brought before them at the Company’s Annual and Special Meeting of Shareholders (“AGM”) held on June 25, 2020 in Halifax, Nova Scotia. Details of the AGM are provided below.Appointment of Board and ExecutiveAt the AGM, shareholders voted in favour of Erdene management’s nominees to the board of directors, with details of the proxy voting results as follows:Following the AGM, Erdene’s board of directors appointed its officers for the coming year, namely: President and Chief Executive Officer – Peter Akerley; Chairman of the Board – T. Layton Croft; Chief Financial Officer – Robert Jenkins; and Corporate...
TELA Bio Announces Pricing of Public Offering of Common Stock
Written by Customer Service on . Posted in Public Companies.
MALVERN, Pa., June 25, 2020 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share for gross proceeds of $48.0 million, before underwriting discounts and commissions. In addition, TELA has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock in the offering. All shares of common stock are being offered by TELA. The offering is expected to close on June 30, 2020, subject to the satisfaction of customary closing conditions.Jefferies LLC and Piper...
ADOMANI’s Commitment to Stakeholders
Written by Customer Service on . Posted in Public Companies.
CORONA, Calif. , June 25, 2020 (GLOBE NEWSWIRE) — via NetworkWire – ADOMANI, Inc. (OTCQB: ADOM), a provider of new zero-emission, purpose-built electric vehicles and drivetrain solutions, today released the following statement to its stakeholders:ADOMANI’s Zero-Emission SolutionsADOMANI provides new zero-emission electric vehicles and is a provider of zero-emission electric drivetrain systems for integration in medium to heavy-duty commercial fleet vehicles and re-power drivetrain system conversion kits for replacement in combustion-powered vehicles. Our zero-emission electric vehicles are focused on reducing the total cost of vehicle ownership. We help fleet operators unlock the benefits of green technology while addressing the challenges of traditional fuel price instability and local, state, and federal environmental regulatory...
